Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2019

Open Access 01-12-2019 | Glioblastoma | Review

Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis

Authors: Yu-ying Lei, Yi-tong Li, Qi-lu Hu, Juan Wang, Ai-xia Sui

Published in: World Journal of Surgical Oncology | Issue 1/2019

Login to get access

Abstract

Background

In some malignant tumors, a high neutrophil-to-lymphocyte ratio (NLR) is connected with unfavorable prognosis. Nevertheless, the prognostic value of the NLR in gliomas remains disputed. The clinical significance of the NLR in gliomas was investigated in our study.

Methods

The databases, PubMed, Embase, and the Cochrane Library, were searched using words like “glioma,” “glioblastoma,” “neutrophil-to-lymphocyte ratio,” and others through May 2019. We evaluated the significance of NLR on overall survival (OS) of patients with gliomas in our study.

Results

Finally, 16 cohorts with 2275 patients were analyzed. The pooled analysis revealed that an elevated NLR was connected with unfavorable OS (hazards ratio (HR): 1.43, 95% confidence interval (CI): 1.27–1.62) outcomes of patients with gliomas.

Conclusion

A high NLR can be considered a high-risk prognostic factor in gliomas, and more adjuvant chemotherapy should be recommended for high-risk patients.
Appendix
Available only for authorised users
Literature
1.
QT O, H G LS, SM V, JS B-S. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–14.CrossRef
2.
Stupp R, Mason WP, MJvd B, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRef
3.
Kawano H, Hirano H, Yonezawa H, Yunoue S, Yatsushiro K, Ogita M, et al. Improvement in treatment results of glioblastoma over the last three decades and benefi cial factors. Br J Neurosurg. 2015;29:206–12.CrossRef
4.
O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–36.CrossRef
5.
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–30.CrossRef
6.
McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.CrossRef
7.
Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.CrossRef
8.
Liu X, Qu JK, Zhang J, Yan Y, Zhao XX, Wang JZ, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: a meta-analysis. Medicine. 2017;96(45):e8101.CrossRef
9.
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181–9.CrossRef
10.
Mu S, Ai L, Fan F, Sun C, Hu Y. Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. OncoTargets Ther. 2018;11:499–507.CrossRef
11.
Zhang J, Zhang H-Y, Li J, Shao X-Y, Zhang C-X. The elevated NLR, PLR and PLT May predict the prognosis of patients with colorectal cancer: a systematic review and metaanalysis. Oncotarget. 2017;8(40):68837–46.PubMedPubMedCentral
12.
Zhou Q, Hong L, Zuo M-Z, He Z. Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients. Oncotarget. 2017;8(40):68938–49.PubMedPubMedCentral
13.
Semeniuk-Wojtas A, Lubas A, Stec R, Syrylo T, Niemczyk S, Szczylik C. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer. 2018;16(3):e685–e93.CrossRef
14.
Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, Abufaraj M, et al. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World J Urol. 2018;36(7):1019–29.CrossRef
15.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRef
16.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRef
17.
Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neuro-Oncol. 2013;114(1):149–54.CrossRef
18.
Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer. 2015;15:617.CrossRef
19.
Auezova R, Ryskeldiev N, Doskaliyev A, Kuanyshev Y, Zhetpisbaev B, Aldiyarova N, et al. Association of preoperative levels of selected blood inflammatory markers with prognosis in gliomas. OncoTargets Ther. 2016;9:6111–7.CrossRef
20.
Kaya V, Yildirim M, Yazici G, Yalcin AY, Orhan N, Guzel A. Prognostic significance of indicators of systemic inflammatory responses in glioblastoma patients. Asian Pac J Cancer Prev. 2017;18(12):3287–91.PubMedPubMedCentral
21.
Lopes M, Carvalho B, Vaz R, Linhares P. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neuro-Oncol. 2017;136(1):173–80.CrossRef
22.
Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar B-A, et al. Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J Neuro-Oncol. 2017;132(3):463–71.CrossRef
23.
Wang PF, Song HW, Cai HQ, Kong LW, Yao K, Jiang T, et al. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival. Oncotarget. 2017;8(30):50117–23.PubMedPubMedCentral
24.
Wiencke JK, Koestler DC, Salas LA, Wiemels JL, Roy RP, Hansen HM, et al. Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clin Epigenetics. 2017;9:10.CrossRef
25.
Wang J, Xiao W, Chen W, Hu Y. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioma. EXCLI J. 2018;17:505–12.PubMedPubMedCentral
26.
Weng W, Chen X, Gong S, Guo L, Zhang X. Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival. Neurol Res. 2018;40(11):917–22.CrossRef
27.
Yersal O, Odabasi E, Ozdemir O, Kemal Y. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma. Mol Clin Oncol. 2018;9(4):453–8.PubMedPubMedCentral
28.
29.
Ng SSQ, Chua GWY, Kusumawidjaja G, Wong FY, Tham CK, Chua ET, et al. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic biomarkers for elderly patients with glioblastoma treated with chemoradiation. Int J Radiat Oncol. 2017;99(2):E97.CrossRef
30.
YANG T, MAO P, CHEN X, NIU X, XU G, BAI X, et al. Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram. Oncol Lett. 2019;17:2516–22.PubMed
31.
32.
Gan Y, Zhou X, Niu X, Li J, Wang T, Zhang H, et al. Neutrophil/lymphocyte ratio is an independent prognostic factor in elderly patients with high-grade gliomas. World Neurosurg. 2019;127:e261–e7.CrossRef
33.
HT PETRIE, LW KLASSEN, HD KAY. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134(1):230–4.
34.
EL-HAG A. CLARK' RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139(7):2406–13.PubMed
35.
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.CrossRef
Metadata
Title
Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis
Authors
Yu-ying Lei
Yi-tong Li
Qi-lu Hu
Juan Wang
Ai-xia Sui
Publication date
01-12-2019
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1686-5

Other articles of this Issue 1/2019

World Journal of Surgical Oncology 1/2019 Go to the issue

Case report

Cystic lymphangioma in the peripheral jejunal mesentery in an adult and excision with laparoscopic-assisted surgery: a case report

Research

Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection

Research

Optimal diagnostic method using multidetector-row computed tomography for predicting lymph node metastasis in colorectal cancer

Research

Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk

Research

The role of three-dimensional reconstruction in laparoscopic partial nephrectomy for complex renal tumors

Research

Modified score based on revised Tokuhashi score is needed for the determination of surgical intervention in patients with lung cancer metastases to the spine